Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial

K Fischer; J Bahlo; AM Fink; V Goede; CD Herling; P Cramer; P Langerbeins; J Von Tresckow; A Engelke; C Maurer; G Kovacs; M Herling; E Tausch; KA Kreuzer; B Eichhorst; S Böttcher; JF Seymour; P Ghia; P Marlton; M Kneba; CM Wendtner; H Döhner; S Stilgenbauer; M Hallek

Journal article

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial

K Fischer, J Bahlo, AM Fink, V Goede, CD Herling, P Cramer, P Langerbeins, J Von Tresckow, A Engelke, C Maurer, G Kovacs, M Herling, E Tausch, KA Kreuzer, B Eichhorst, S Böttcher, JF Seymour, P Ghia, P Marlton, M Kneba Show all

Blood | AMER SOC HEMATOLOGY | Published : 2016

DOI: 10.1182/blood-2015-06-651125

Abstract

Despite promising results with targeted drugs, chemoimmunotherapy with fludarabine, cyclophosphamide (FC), and rituximab (R) remains the standard therapy for fit patients with untreated chronic lymphocytic leukemia (CLL). Herein, we present the long-term follow-up of the randomized CLL8 trial reporting safety and efficacy of FC and FCR treatment of 817 treatment-näivepatientswithCLL.The primary end pointwas progressionfree survival (PFS). With a median follow-up of 5.9 years, median PFS were 56.8 and 32.9 months for theFCRand FCgroup (hazardratio[HR], 0.59; 95%confidence interval [CI], 0.50- 0.69, P< .001).Median overall survival (OS)was not reached for the FCRgroup and was 86.0 months for t..

View full abstract